Application of Dexmedetomidine Intravenously Infusion Before Induction of Anesthesia in Segmentectomy of Lung Cancer Patients.

Objective: To study the application of dexmedetomidine in pulmonary segment resection in lung cancer patients.

Methods: A total of 120 patients with lung cancer who underwent segmentectomy in our hospital from January 2021 to January 2022 were selected and divided into a control group (60 cases) and a study group (60 cases) according to the lottery method. Early lung cancer was diagnosed by histopathology and imaging, which was in line with the indication of segmental pneumonectomy, and was not treated by radiotherapy, chemotherapy, and other means.Exclusion criteria: Patients with coagulation system diseases, middle and late-stage patients and distant metastasis were excluded. Before induction of anesthesia, the control group was injected with normal saline 0.6 μg/kg, and the study group was injected with dexmedetomidine 0.6 μg/kg. Before anesthesia induction (T0), ventilation for 0.5 h (T2), ventilation for 1 h (T2), and immediately after surgery (T3), the changes of hemodynamics, physiological stress, and internal environment stability indexes were analyzed, and adverse reactions and pulmonary symptoms were counted. Incidence of injury and cognitive impairment.

Results: The comparison of the observation indicators at T0 time point of the two patient groups was insignificant (P > .05). The T1-T3 point had no significant fluctuation in the study group compared with the T0 point (P > .05). The T1-T3 point in the control group was significantly higher than the T0 point MAP, HR, PaO2, SOD, Cor decreased, PaCO2, MDA, ACTH increased, with obvious fluctuations (P < .05); T1 ~ T3, compared with the control group, the study group MAP, HR, PaO2, SOD, Cor increased, PaCO2, MDA, ACTH decreased (P < .05). There was no significant comparison of adverse reactions between the two groups (P > .05). Compared with the control group, lung injury and cognitive impairment incidence in the study group was lower (P < .05).

Conclusion: Before anesthesia induction, intravenous injection of dexmedetomidine can maintain hemodynamic and internal environment stability in lung cancer patients, reduce stress damage to the body, and reduce the incidence of lung injury and cognitive impairment, with high application value. This will reduce the pain of patients in clinical.